
Joe Giordano, surgeon who helped save President Reagan's life after assassination attempt, has died
He died on June 24 at a hospital in Washington, D.C. from an infection related to a lengthy illness, his family said.
Giordano was in charge of The George Washington University Hospital's trauma teams that treated
Reagan
after the president had been shot and badly wounded on March 30, 1981. Over the course of several dramatic hours, doctors stabilized Reagan, retrieved a bullet an inch from his heart and stanched massive internal bleeding.
'Dr. Giordano and the doctors at GW, without them, Ronald Reagan would have died,' said Jerry Parr, the president's lead Secret Service agent at the time, in a 2010 interview for the book '
Rawhide Down
.'
Revamps GW
emergency room
Giordano, the grandson of Italian immigrants, was born and raised in New Jersey. He graduated from Georgetown University in 1961 and six years later obtained a medical degree from
Jefferson Medical College in Philadelphia
.
After a stint in the U.S. Army, he joined GW as a vascular surgeon. A few weeks before he started in 1976, GW's chief of surgery told Giordano that he would have another job — fixing and managing the emergency room.
'The handling of trauma patients down there is a real mess,' his boss said.
Giordano quickly discovered that assessment was correct. Inexperienced doctors were leading inefficient medical teams. Care was haphazard. Giordano watched as at least one patient died because treatment was rendered too slowly.
Seeking out experts, he spent a month working at what would become the R Adams Cowley Shock Trauma Center at the University of Maryland. The teams at Shock Trauma operated with speed and precision. They were methodical. He brought the approach to GW. Soon, the hospital's trauma center was regarded as among the best in the country.
'We had everything going like clockwork,' said Dr. David Gens, who helped treat Reagan and went on to a long career in trauma surgery. 'Joe had us properly trained. We had the right protocols. Everyone had a job. Organization and time are essential. So that when something happened, when the president came in, we were well organized. Thanks in part to Joe's foresight, we saved the president's life.'
'STAT to the ER'
It was a typical March Monday for Giordano when a would-be assassin, John Hinckley, Jr., opened fire on Reagan as the president left a speech at the Washington Hilton Hotel. Parr, the Secret Service agent, shoved Reagan into a limousine, and it hurtled from the scene. On the ride back to the White House, Parr realized Reagan had been hurt, perhaps from being flung into the armored Lincoln. Not knowing the extent of the injuries — doctors would soon discover he had been shot — Parr directed the limousine to the hospital.
At GW Giordano was treating a patient when the intercom began blaring: 'Dr. Giordano, STAT to the ER. Dr. Giordano, STAT to the ER.' Though he had turned over responsibility for running the emergency room to another doctor, Giordano was still in charge of the trauma teams. He knew something must be terribly wrong for him to be summoned that way.
In the ER, he found a man he recognized as the president on gurney. Nurses had already cut off Reagan's clothes and inserted IV lines. Strangely, the first thing that Giordano noticed about the president was his dark hair. It seemed so natural. 'I wondered,' Giordano recalled in a 2010 interview, 'if he dyed it.'
'How are you doing, Mr. President?' he asked.
'I'm having trouble breathing,' Reagan replied.
Bleeding won't stop
Gens, a chief surgical resident, provided Giordano a quick summary of the situation: The president had been shot in the left side, his chest was filling with blood and they were about to insert a chest tube to drain the chest cavity.
Giordano did not hesitate. 'You better let me do this one.' He typically would have let a resident handle such a procedure, but he felt it would be irresponsible to put such pressure on young doctors. He made an incision eight inches below Reagan's left armpit and inserted the tube.
It relieved pressure on Reagan's lung and allowed him to breathe more easily. But the bleeding did not stop. Doctors decided they had to operate.
Giordano and Gens performed a peritoneal lavage — known as a 'belly tap' — and ensured that Reagan's abdomen was clear of blood. They then turned over the patient to a chest surgeon,
Dr. Benjamin Aaron
, who halted the bleeding and retrieved the bullet.
Reagan spent 11 days at GW and fully recovered from his wounds. Three others were injured in the shooting: White House Press Secretary Jim Brady; Secret Service agent Timothy McCarthy; and Thomas Delahanty, a police officer.
Hinckley was found not guilty by reason of insanity. He was confined at a psychiatric hospital until a
federal judge in 2022 ordered
his unconditional release.
'Today, Mr. President, we are all Republicans'
Giordano would go on to become GW's chairman of surgery, a post he held for 18 years before retiring in 2010.
That same year, he joined the board at
Partner for Surgery
, a nonprofit group that arranges surgery for people living in rural Guatemala. Tapping his contacts in the medical community, Giordano recruited doctors and nurses to travel to the Central American country to provide the badly needed medical services, said Frank Peterson, the group's founder. Giordano also led several medical teams on such missions.
'The one word I would use to describe him is humanitarian,' Peterson said. 'He had the skills and capabilities that made a world of difference to people who were in need.'
Though Giordano played a decisive role in saving Reagan's life, the physician may best be remembered for a line he delivered in the operating room.
Just before he was administered anesthesia, Reagan dramatically got up on an elbow, took off his oxygen mask and said, 'I hope you are all Republicans.'
Giordano, a staunch liberal, didn't miss a beat: 'Today, Mr. President, we are all Republicans.'
Years later, the surgeon jokingly reflected that 'it was okay to be a Republican for a day, especially that day.'

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Fox News
8 hours ago
- Fox News
Massive bee swarm sends three people to hospital in critical condition, 24 injured
A buzzing commotion has disrupted a picturesque town this summer. A swarm of bees left 24 people injured in an unusual attack on Sunday, The Associated Press (AP) reported. Those walking through Aurillac, a quaint French community, were stung over a 30-minute period, with three people in critical condition evacuated to a hospital. Some 26,000 people were living in the alp town in 2022, according to the French National Institute of Statistics and Economic Studies. Aurillack is located in the Auvergne-Rhône-Alpes region of France. Pierre Mathonier, mayor of Aurillac, told a local broadcaster that those who were left in critical condition are improving, AP reported. One victim was a 78-year-old who suffered cardiorespiratory arrest and had to be resuscitated. That individual is now in stable condition, while the other two are said to be in "good health," per the mayor. Mathonier added the attack could have been related to the bees becoming more aggressive over the years. Over a decade ago, Asian hornets were harassing a beehive that was on the roof terrace of a downtown hotel, he told AP. Lt. Col. Michel Cayla, who runs the local fire services, said the attack was "impressive" and he has never seen an attack of this scale. Cayla told French broadcaster TF1, "In terms of the number of victims, the panic among the people and the severity of some of the injuries, it was impressive," as AP reported. Bee sting symptoms are mostly "minor." Victims can experience instant, sharp, burning pain, as well as a welt and swelling, according to the Mayo Clinic. The CDC predicted an annual average of 62 deaths due to bee and hornet stings between 2000-2017 in the United States. The beehive has been removed and relocated outside the town, according to AP.


San Francisco Chronicle
8 hours ago
- San Francisco Chronicle
Swiss medicines authority issues first approval for antimalarial drug for treatment of infants
GENEVA (AP) — Switzerland's medical products authority has granted the first approval for a malaria medicine designed for small infants, touted as an advance against a disease that takes hundreds of thousands of lives — nearly all in Africa — each year. Swissmedic gave a green light Tuesday for the medicine from Basel-based pharmaceutical company Novartis for treatment of babies with body weights between 2 and 5 kilograms (nearly 4½ to 11 pounds), which could pave the way for hard-hit African nations to follow suit in coming months. The agency said that the decision is significant in part because it's only the third time it has approved a treatment under a fast-track authorization process, in coordination with the World Health Organization, to help developing countries access needed treatment. The newly approved medication is a lower dose version of a tablet previously approved for other age groups, including older children. Dr. Quique Bassat, a malaria expert not affiliated with the Swiss review, said the burden of malaria in very young children is 'relatively low' compared to older kids. But access to such medicines is important to all, he said. 'There is no doubt that any child of whichever age — and particularly very, very young ones or very light-weighted ones — require a treatment,' said Bassat, the director- general of the Barcelona Institute for Global Health, known as ISGlobal. Up to now, antimalarial drugs designed for older children have been administered to small infants in careful ways to avoid overdose or toxicity, in what Bassat called a 'suboptimal solution' that the newly designed medicine could help rectify. 'This is a drug which we know is safe, we know works well, and therefore it will just be available as a new version for a specific age group,' he said. Ruairidh Villar, a Novartis spokesperson, said that eight African countries took part in the assessment and are expected to approve the medicine within 90 days. The company said that it's planning on a rollout on a 'largely not-for-profit basis' in countries where malaria is endemic. Dr. Bhargavi Rao, co-director of the Malaria Centre at the London School of Hygiene and Tropical Medicine, noted that malaria cases continue to rise — especially in crisis-hit countries — despite new vaccines and programs targeting the mosquitoes that spread the parasite. She said access strategies for the new medicine must include a look at where needs are greatest, and urged clarity on pricing. 'We need transparency around what Novartis' 'largely not for profit' statement means including publicly available pricing, which countries will benefit and how long for,' she wrote in an email. Still, she said it was 'significant to finally have a suitable and safe treatment for very young children — more than 20 years since WHO first pre-qualified CoArtem for older age groups. She noted the announcement comes as resistance to antimalarials has been growing and many traditional donor countries have been sharply cutting outlays for global health — including for malaria programming and research. The mosquito-borne illness is the deadliest disease in Africa, whose 1.5 billion people accounted for 95% of an estimated 597,000 malaria deaths worldwide in 2023, according to WHO. More than three-quarters of those deaths were among children.
Yahoo
8 hours ago
- Yahoo
Swiss medicines authority issues first approval for antimalarial drug for treatment of infants
GENEVA (AP) — Switzerland's medical products authority has granted the first approval for a malaria medicine designed for small infants, touted as an advance against a disease that takes hundreds of thousands of lives — nearly all in Africa — each year. Swissmedic gave a green light Tuesday for the medicine from Basel-based pharmaceutical company Novartis for treatment of babies with body weights between 2 and 5 kilograms (nearly 4½ to 11 pounds), which could pave the way for hard-hit African nations to follow suit in coming months. The agency said that the decision is significant in part because it's only the third time it has approved a treatment under a fast-track authorization process, in coordination with the World Health Organization, to help developing countries access needed treatment. The newly approved medication is a lower dose version of a tablet previously approved for other age groups, including older children. Dr. Quique Bassat, a malaria expert not affiliated with the Swiss review, said the burden of malaria in very young children is 'relatively low' compared to older kids. But access to such medicines is important to all, he said. 'There is no doubt that any child of whichever age — and particularly very, very young ones or very light-weighted ones — require a treatment,' said Bassat, the director- general of the Barcelona Institute for Global Health, known as ISGlobal. Up to now, antimalarial drugs designed for older children have been administered to small infants in careful ways to avoid overdose or toxicity, in what Bassat called a 'suboptimal solution' that the newly designed medicine could help rectify. 'This is a drug which we know is safe, we know works well, and therefore it will just be available as a new version for a specific age group,' he said. Ruairidh Villar, a Novartis spokesperson, said that eight African countries took part in the assessment and are expected to approve the medicine within 90 days. The company said that it's planning on a rollout on a 'largely not-for-profit basis' in countries where malaria is endemic. Dr. Bhargavi Rao, co-director of the Malaria Centre at the London School of Hygiene and Tropical Medicine, noted that malaria cases continue to rise — especially in crisis-hit countries — despite new vaccines and programs targeting the mosquitoes that spread the parasite. She said access strategies for the new medicine must include a look at where needs are greatest, and urged clarity on pricing. 'We need transparency around what Novartis' 'largely not for profit' statement means including publicly available pricing, which countries will benefit and how long for,' she wrote in an email. Still, she said it was 'significant to finally have a suitable and safe treatment for very young children — more than 20 years since WHO first pre-qualified CoArtem for older age groups. She noted the announcement comes as resistance to antimalarials has been growing and many traditional donor countries have been sharply cutting outlays for global health — including for malaria programming and research. The mosquito-borne illness is the deadliest disease in Africa, whose 1.5 billion people accounted for 95% of an estimated 597,000 malaria deaths worldwide in 2023, according to WHO. More than three-quarters of those deaths were among children.